Novo Nordisk sues competitor Eli Lilly over GLP-1 advertising

Novo Nordisk sued Eli Lilly over claims that its weight-loss medications work better than Novo's, alleging deceptive advertising with outdated trials. The lawsuit, filed in New Jersey, accuses Lilly of comparing high doses of Zepbound to lower doses of Wegovy and Ozempic. Novo seeks a court order to stop the ads and a correction campaign, with a potential preliminary injunction if compliance is not voluntary.